PharmaNet Development Group Experts Share Insights at the 19th Annual Partnerships in Clinical Trials Conference in April 2010

PRINCETON, N.J., March 31 /PRNewswire/ -- PharmaNet Development Group, Inc., a leading provider of clinical development services to pharmaceutical, biotechnology, generic drug and medical device companies, today announced its participation at the 19th Annual Partnerships in Clinical Trials Conference in Orlando, Florida from April 12-14, 2010. In addition to its presence at booth 215, PharmaNet experts will discuss a variety of topics during the conference, lead a roundtable discussion, and participate in an industry panel to discuss the future of the industry.

Monday April 12, 2010

Designing Safe and Efficient Phase I Studies to Expedite Clinical Development

Mario Tanguay, BPharm, PhD, Vice President, Scientific and Regulatory Affairs, Anapharm, a PharmaNet Company will conduct a workshop that will guide attendees through some of issues with study design and  regulatory requirements for Phase I clinical studies with new chemical entities.

How Can a CRO Become a Partner of Choice?

David Fenske, Executive Director, Worldwide Proposal Development will lead a lively roundtable discussion about how CROs strengthen relationships with sponsors.

Tuesday April 13, 2010

CEOs Unplugged: Risk Mitigation and Margin Preservation

Jeffrey P. McMullen, Chief Executive Officer, PharmaNet Development Group will serve as a panelist in this discussion on the outlook for the CRO industry in 2010 and beyond.

Meeting Global Regulatory Requirements in Early Phase Studies

Bengt R. Danielsson, MD, PhD, Vice President, PharmaNet Consulting, will present ICH guidelines for Explorative trials and new principles for selecting starting dose and mitigating risks for drugs acting by novel mechanisms. Andrew Chang, PhD, Executive Director, PharmaNet Consulting, will discuss regulatory challenges for early clinical development in emerging markets with special focus on Asia and China.

Wednesday April 14, 2010

Contrasting ePRO Data Collection Methodologies

Charles Gasman, Executive Director, Interactive Technologies, will make a presentation at the eClinical Technology Summit; a co-located event with Partnerships in Clinical Trials. His presentation will explore ePRO (Electronic Patient Reported Outcomes) methodologies, their advantages and disadvantages, and provide some guidance on selecting the optimal methodology for different types of studies.

Conference attendees are invited to visit booth number 215 where PharmaNet Development Group's international team of experts will discuss how the Company helps clients achieve their goal of developing safe and effective therapeutics for patients.

About PharmaNet Development Group, Inc.

PharmaNet Development Group, Inc., a global drug development services company, provides a comprehensive range of services to the pharmaceutical, biotechnology, generic drug and medical device industries. The Company offers early and late stage consulting, Phase I clinical studies and bioanalytical analyses, and Phase II, III and IV clinical development programs. With approximately 2,300 employees and more than 41 facilities throughout the world, PharmaNet is a recognized leader in outsourced clinical development. For more information, please visit our website at www.pharmanet.com.  

SOURCE PharmaNet Development Group, Inc.